

NATIONAL QUALITY FORUM

National Voluntary Consensus Standards for Patient Safety Measures

Medication Safety Technical Advisory Panel Conference Call

August 10 and 17, 2010

Please use the following information to access the conference call line:

Participant Dial-in Number: 1-913-312-1483

Conference ID: 9761540

Website: <http://www.myeventpartner.com/NQForum9>

You will be prompted to enter your name, location (optional), and e-mail address. Then click on "Click here to enter presentation."

For technical support, please e-mail nqf@commpartners.com.

AGENDA

Day 1: August 10

- 2:00 pm** **Welcome and Introductions**
David P. Nau, PhD, RPh, CPHQ (Chair)
Peter Angood, MD, Senior Advisor, Patient Safety
Heidi Bossley, MSN, MBA, Managing Director, CDP
Andrew Lyzenga, MPP, Project Manager
Elisa E. Munthali, MPH, Project Manager
Eric Colchamiro, MPA, Research Analyst
- 2:15 pm** **Project Overview and Measure Evaluation Criteria Review**
Andrew Lyzenga
- 2:30 pm** **Disclosures of Interest**
Ann Hammersmith, JD, General Counsel
- 2:40 pm** **Technical Advisory Panel Review**
- **PSM-009-10:** Medication Administration Variance (ASC Quality Collaboration)
 - **PSM-010-10:** Querying and Counseling about Anti-Epileptic Drug (AED) Side-Effects (American Academy of Neurology)
- 3:40 pm** **NQF Member/Public Comment**
- 3:45 pm** **Technical Advisory Panel Review**
- **PSM-023-10:** Patient(s) with hepatitis C infection taking interferon that had periodic serum ALT monitoring (Ingenix, Inc.)
 - **PSM-024-10:** Patient(s) with hepatitis C infection taking interferon that had periodic CBC with differential monitoring (Ingenix, Inc.)

NATIONAL QUALITY FORUM

- **PSM-025-10:** Patient(s) with HIV infection taking antiretroviral medications that had a serum ALT or AST test in last 6 reported months (Ingenix, Inc.)
- **PSM-026-10:** Patient(s) with HIV infection taking antiretroviral medications that had a CBC in last 6 reported months (Ingenix, Inc.)

4:45 pm **NQF Member/Public Comment**

4:50 pm **Recap**

5:00 pm **Adjourn**

Day 2: August 17

1:00 pm **Welcome and Introductions**
David P. Nau, PhD, RPh, CPHQ (Chair)

1:10 pm **Technical Advisory Panel Review (40 min)**

- **PSM -017-10:** Patient(s) with rheumatoid arthritis taking methotrexate, sulfasalazine, or leflunomide that had serum ALT or AST test in last 3 reported months. (Ingenix, Inc.)
- **PSM -018-10:** Patient(s) with rheumatoid arthritis taking methotrexate or sulfasalazine that had a serum creatinine in last 6 reported months. (Ingenix, Inc.)
- **PSM -019-10:** Patient(s) with rheumatoid arthritis taking methotrexate, sulfasalazine, gold, or leflunomide that had a CBC in last 3 reported months. (Ingenix, Inc.)

1:50 pm **NQF Member/Public Comment**

1:55 pm **Technical Advisory Panel Review (40 min)**

- **PSM-020-10:** Patient(s) with inflammatory bowel disease taking methotrexate, azathioprine or mercaptopurine that had serum ALT or AST test in last 6 reported months (Ingenix, Inc.)
- **PSM-030-10:** Patient(s) with inflammatory bowel disease taking methotrexate, sulfasalazine, mercaptopurine, or azathioprine that had a CBC in last 3 reported months (Ingenix, Inc.)
- **PSM-031-10:** Patient(s) with inflammatory bowel disease taking methotrexate that had a serum creatinine in last 6 reported months (Ingenix, Inc.)

2:35 pm **NQF Member/Public Comment**

2:40 pm **Technical Advisory Panel Review**

- **PSM-027-10:** Adult patient(s) with atrial fibrillation taking amiodarone that had serum ALT or AST test in last 12 reported months (Ingenix, Inc.)
- **PSM-028-10:** Adult patient(s) taking a statin-containing medication or nicotinic acid that had an annual serum ALT or AST test (Ingenix, Inc.)
- **PSM-029-10:** Adult patient(s) taking warfarin that had three or more prothrombin time tests in last 6 reported months (Ingenix, Inc.)

NATIONAL QUALITY FORUM

3:20 pm **NQF Member/Public Comment**

3:25 pm **Technical Advisory Panel Review**

- **PSM-021-10:** Adult patient(s) with multiple sclerosis taking interferon that had a serum ALT/AST test in last 12 reported months (Ingenix, Inc.)
- **PSM-022-10:** Adult patient(s) with multiple sclerosis taking interferon that had a CBC in last 12 reported months (Ingenix, Inc.)

3:50 pm **NQF Member/Public Comment**

3:55 pm **Wrap-up/Next Steps**

4:00 pm **Adjourn**